How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

365 results for

Intraocular Carbonic Anhydrase Inhibitor

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)

Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) period. Washout period: 20 hours. Patients in the period 2: the pharmacological intervention change to the opposite therapy for 30 days Condition or disease Intervention/treatment Phase Primary Open Angle Glaucoma Ocular Hypertension Drug: PRO-122 Drug: Krytantek Ofteno® Phase 3 Detailed Description: The American Academy of Ophthalmology Glaucoma Panel: The primary open angle glaucoma (POAG) is a progressive, chronic optic neuropathy in adults in which intraocular pressure (IOP) and other currently

2017 Clinical Trials

62. Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy

Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Ophthalmic Solutions Pharmaceutical Solutions Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) 20, 2017 Last Update Posted : July 11, 2017 Sponsor: University Hospital of Patras Information provided by (Responsible Party): Constantinos D. Georgakopoulos, MD, PhD, University Hospital of Patras Study Details Study Description Go to Brief Summary: To compare the efficacy of a Brinzolamide/Brimonidine fixed combination (FC) with Brimonidine 0.2% in preventing intraocular pressure (IOP) elevations after neodymium: yttrium-aluminum-garnet (Nd:YAG) laser posterior capsulotomy. Condition

2017 Clinical Trials

63. PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)

(e.g. degenerations, diabetic retinopathy, retinal detachment) Ability Visual 20/200 or worse in any of the eyes. Subject with only one eye Eye diseases that contraindicate the use of Beta-blocker (BB) Alpha-adrenergic agonist (AA) or Carbonic anhydrase inhibitors (CAIs) Intraocular surgery less or equal to 6 months prior to the study Laser intraocular surgery less or equal to 3 months prior to the study Any abnormality preventing reliable applanation tonometry Unstable or uncontrolled (...) Ocular Hypertension Eye Diseases Pharmaceutical Solutions Ophthalmic Solutions Timolol Brimonidine Tartrate Dorzolamide Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Carbonic Anhydrase Inhibitors Enzyme Inhibitors

2017 Clinical Trials

64. Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma

of investigational product; or pilocarpine or carbonic anhydrase inhibitors within 7 days before the first dose of investigational product. Participant has a history of angle closure, ocular surgery, microinvasive glaucoma surgery device insertion, or laser surgery, except for the following procedures, which are allowed: uncomplicated cataract surgery, laser peripheral iridotomy with resultant angle of Shaffer grade 3 or 4, and postcataract neodymium-doped yttrium-aluminum-garnet (Nd:YAG) laser posterior (...) Antibodies, Drop Comfort Assessment and Ophthalmologic Examinations Reported as AEs [ Time Frame: From start of study drug administration to 9 days after last study drug administration ] The number of participants with clinically significant abnormalities in vital sign measurements, electrocardiogram (ECG), clinical laboratory assays, antidrug antibodies, drop comfort assessment, and ophthalmologic examinations reported as AEs will be reported. Secondary Outcome Measures : Change in Intraocular Pressure

2017 Clinical Trials

65. Additive Effect of Twice-daily Brinzolamide 1% / Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma

of Pharmacological Action Physiological Effects of Drugs Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) Government. Read our for details. ClinicalTrials.gov Identifier: NCT03150160 Recruitment Status : Completed First Posted : May 12, 2017 Results First Posted : February 25, 2019 Last Update Posted : February 25, 2019 Sponsor: Novartis Pharmaceuticals Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals ) Study Details Study Description Go to Brief Summary: The purpose of this study was to determine the incremental intraocular pressure (IOP) lowering that is achieved when

2017 Clinical Trials

66. Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma (PubMed)

: beta-adrenergic antagonists, alpha-adrenergic agonists, cholinergic agonists, carbonic anhydrase inhibitors, and prostaglandin analogs. Issues with existing drugs include failure to achieve target IOP with monotherapy, drug-related side effects, and low patient compliance with multiple daily administration of eye drops. In recent years, the scientific and medical community has seen encouraging development of novel classes of drugs for primary OAG, the majority of which lower IOP by targeting (...) Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma Primary open-angle glaucoma (OAG) affects approximately 45 million people worldwide and more than 2.5 million people aged 40 years or older in the United States. Pharmacologic treatment for glaucoma is directed towards lowering intraocular pressure (IOP) to slow disease progression and delay visual field loss. Current medical treatment options for the lowering of IOP include the following classes of topical medications

Full Text available with Trip Pro

2017 The Yale journal of biology and medicine

67. Patient satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution: a survey study in patients with glaucoma in China (PubMed)

with glaucoma treated with BTFC for 1-3 months. Five hundred patients answered a questionnaire concerning their demographic characteristics, history of glaucoma and topical glaucoma treatment, and use of BTFC. The primary endpoint was patient satisfaction with BTFC assessed on a 10-point scale (1= very dissatisfied, 10= very satisfied).Patients received BTFC alone (65%) or with other treatments (35%), most commonly a carbonic anhydrase inhibitor. Most patients (87%) used BTFC as a replacement for other (...) with their previous treatment. Mean satisfaction scores were significantly higher for BTFC than for previous treatments among all patients (7.8 versus 6.0; P<0.0001) and within patient subgroups based on demographic characteristics, pattern of BTFC use, and previous treatment.Patients were highly satisfied with BTFC used alone or concomitantly with another topical medication. Patients previously treated with a β-blocker, prostaglandin analog, carbonic anhydrase inhibitor, α-adrenergic agonist, or combination

Full Text available with Trip Pro

2017 Patient preference and adherence

68. A review of additivity to prostaglandin analogs: fixed and unfixed combinations. (PubMed)

A review of additivity to prostaglandin analogs: fixed and unfixed combinations. Prostaglandin analogs are currently the first-line agents in the medical treatment of glaucoma. Frequently, more than one drug is needed to control intraocular pressure. Beta-blockers, topical carbonic anhydrase inhibitors, and alpha-adrenergic agonists are commonly used in addition to prostaglandin analogs. Topical carbonic anhydrase inhibitors are more effective in lowering intraocular pressure at trough than (...) alpha-adrenergic agonists. Although similarly effective as topical carbonic anhydrase inhibitors during the day, adequate nocturnal intraocular pressure reduction with beta-blockers is controversial. Three fixed combinations of prostaglandins with timolol (0.005% latanoprost with 0.5% timolol, 0.004% travoprost with 0.5% timolol, and 0.03% bimatoprost with 0.5% timolol) are available. Fixed-combination therapy has advantages over multi-drop, multi-bottle therapy in terms of patient convenience

2017 Survey of Ophthalmology

69. Glaucoma

. Pharmacological treatments which reduce the intraocular pressure include ocular beta-adrenoceptor blocking drugs, prostaglandin analogues, miotics, sympathomimetics, and ocular and systemic carbonic anhydrase inhibitors. There are little or no data on pregnancy outcomes following the use of these medications in pregnancy and an evidence-based assessment of risk to the developing fetus with maternal exposure is therefore not possible. However, untreated or under-treated glaucoma could potentially lead

2014 UK Teratology Information Service

70. Glaucoma: brinzolamide/brimonidine combination eye drops

chronic open angle glaucoma. T o stop or reduce disease progression or onset, it may be necessary to combine first-line drugs or add others, such as sympathomimetics, or carbonic anhydrase inhibitors, to control intraocular pressure. Full text of introduction and current guidance. Product overview Brinzolamide/brimonidine combination eye drops (Simbrinza) are licensed for treating chronic open angle glaucoma or ocular hypertension in adults for whom monotherapy did not sufficiently reduce intraocular (...) , latanoprost, tafluprost or travoprost) may be used if a beta-blocker is contraindicated or unsuitable. For people at higher risk of developing glaucoma, for example with an untreated intraocular pressure of more than 21 mmHg and central corneal thickness less than 555 micrometres, a topical prostaglandin analogue is recommended. Alternative pharmacological treatments (prostaglandin analogues, beta-blockers, carbonic anhydrase inhibitors, sympathomimetics, or in some cases, preservative-free preparations

2015 National Institute for Health and Clinical Excellence - Advice

71. 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy

-Arrhythmia Agents Antihypertensive Agents Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) Concomitant therapy with preservative-free talfuprost drops administered once in the evening and dorzolamide/timolol fixed combination drops given twice daily. Evaluation of 24-hour efficacy and ocular surface health after 3 months of therapy. Drug: tafluprost and dorzolamide/timolol Other Name: Saflutan, Taflotan, Cosopt PF Outcome Measures Go to Primary Outcome Measures : Mean 24-hour efficacy (average intraocular pressure readings over 24 hours) [ Time Frame: 3 months ] Secondary Outcome Measures

2016 Clinical Trials

72. The in Vivo Effect of Medical and Surgical Glaucoma Treatments on the Schlemm's Canal Micro-structure

and after cataract surgery Before and after vitrectomy surgery Before and after XEN™ Gel Stent implant The pharmacological branch- Before and during the treatment with prostaglandins analogs Before and during the treatment with alpha blockers Before and during the treatment with beta blockers Before and during the treatment with carbonic anhydrase inhibitor The laser branch- Before and after trabeculoplasty Before and after laser iridotomy Before and after yag capsulotomy laser Condition or disease (...) Before and after XEN™ Gel Stent implant pharmacological branch- Before and during the treatment with prostaglandins analogs Before and during the treatment with alpha blockers Before and during the treatment with beta blockers Before and during the treatment with carbonic anhydrase inhibitor laser branch- Before and after trabeculoplasty Before and after laser iridotomy Before and after yag capsulotomy laser Device: Optical coherence tomography imaging Outcome Measures Go to Primary Outcome Measures

2016 Clinical Trials

73. Effect of Acetazolamide on Optic Nerve Sheath Diameter in Laparoscopic Donor Nephrectomies

Last Update Posted: December 29, 2016 Last Verified: December 2016 Keywords provided by Dr. Ashish Singh Aditya, Postgraduate Institute of Medical Education and Research: optic nerve sheath diameter acetazolamide Additional relevant MeSH terms: Layout table for MeSH terms Intracranial Hypertension Brain Diseases Central Nervous System Diseases Nervous System Diseases Acetazolamide Anticonvulsants Carbonic Anhydrase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action (...) for Heart rate, Blood Pressure, pulse oximetry(Spo2), End Tidal Carbon Dioxide(ETCO2), Train Of Four(TOF) and Bi spectral index(BIS). Post operatively donors were reversed with injection neostigmine and glycopyrrolate. once return of spontaneous ventilation was well established and patient becomes conscious oriented trachea was extubated and donors were shifted to post anaesthetic care unit(PACU). Postoperatively donors were monitored for Heart rate, Blood Pressure, Spo2, Comfort Score, Visual analog

2016 Clinical Trials

74. Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

relevant MeSH terms: Layout table for MeSH terms Glaucoma, Open-Angle Ocular Hypertension Glaucoma Eye Diseases Timolol Brimonidine Tartrate Travoprost Brinzolamide Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Carbonic Anhydrase Inhibitors Enzyme (...) Research Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) dosed twice daily (BID) when added to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) in subjects with open-angle glaucoma or ocular hypertension. Condition or disease Intervention/treatment Phase Open-angle Glaucoma Ocular Hypertension Drug: Brinzolamide 1%/Brimonidine 0.2% suspension Drug: Brinzolamide

2016 Clinical Trials

75. Pressure Difference Between Brain and Eye: a Possible Cause to Normal Tension Glaucoma.

: Subject has normal tension glaucoma in one or both eyes (glaucomatous optic nerve head and corresponding visual field defects) Intraocular pressures before treatment did not exceed 21 mmHg. Occasional measurement up to 24 is accepted. Exclusion Criteria: History of brain disease or brain surgery History of other neurologic or ocular disease causing visual field loss Use of anticoagulants other than acetylsalicylic acid Use of carbonic anhydrase inhibitors Previous lumbar puncture Claustrophobia (...) Description: The trans-lamina cribrosa pressure difference (TLCPD), i.e. the difference between the intraocular pressure (IOP) and the intracranial pressure (ICP) has been suggested as a pathophysiological component in glaucoma. The theory is that high TLCPD, either due to elevated IOP or reduced ICP, can cause glaucomatous damage. Normal tension glaucoma (NTG) patients has been found to have a slightly reduced ICP when measured in horizontal position. However, in a previous study in healthy adult

2016 Clinical Trials

76. Assessment of Depression, Anxiety, and Quality of Life in Singaporean Patients With Glaucoma. (PubMed)

for anxiety included: lower MD in the worse eye (P=0.004) and lower mean VFQ25 score (P=0.004). There was also no significant association between the use of topical β-blockers/carbonic anhydrase inhibitors with depression (P=0.793) or anxiety (P=0.282).There is a relatively high prevalence of depression (30%) and anxiety disorders (64%) among glaucoma patients in Singapore. Female glaucoma patients are more likely to suffer from depression. Other risk factors for depression include higher cup-disc ratio (...) . Patients with other types of glaucoma, and coexisting ocular or psychiatric disorders were excluded.Ophthalmic examination was carried out on all participants, which included best-corrected visual acuity (BCVA), intraocular pressure (IOP), gonioscopy, standard automated perimetry, and optic disc evaluation. Sociodemographic information and treatment histories were also collected.The Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A), and Visual Function Questionnaire (VFQ25

2016 Journal of Glaucoma

77. Acetazolamide

From Related Chapters II. Mechanism Carbonic Anhydrase Inhibitor III. Indications treatment and prevention IV. Contraindications V. Dosing Prevention: 125 mg PO bid Start 24 hours before ascent Continue for 72 hours or until acclimitization to highest sleeping altitude at altitude: 125 mg PO qhs Treatment: 250 mg orally twice daily (up to 400 mg twice daily has been sed) Dose range: 125-250 mg PO qd-tid VI. Adverse Effects Peripheral s (common) Images: Related links to external sites (from Bing (...) . This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See for financial assistance information. Ontology: Acetazolamide (C0000981) Definition (NCI) A sulfonamide derivative with diuretic, antiglaucoma, and anticonvulsant properties. Acetazolamide is a non-competitive inhibitor of carbonic anhydrase, an enzyme found in cells in the proximal

2018 FP Notebook

78. Early Aqueous Suppressant Therapy on Hypertensive Phase Following Glaucoma Drainage Device Procedure: A Randomized Prospective Trial. (PubMed)

Early Aqueous Suppressant Therapy on Hypertensive Phase Following Glaucoma Drainage Device Procedure: A Randomized Prospective Trial. To prospectively evaluate the effect of early aqueous suppression (therapy) on hypertensive phase (HP) and intraocular pressure (IOP) control after implantation of silicone Ahmed glaucoma valve (AGV).Patients who underwent AGV implantation were randomized to initiate therapy (including β-blockers, α-agonists, or carbonic anhydrase inhibitors) when postoperative

2016 Journal of Glaucoma Controlled trial quality: uncertain

79. Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure

herpes simplex keratitis, blepharitis, or acute conjunctivitis) that might interfere with the study; Concomitant contact lens use; Concomitant use of systemic medication that may affect IOP (eg, beta blockers, corticosteroids, calcium channel blockers, ACE inhibitors, or carbonic anhydrase inhibitors); however, systemic antihypertensive medications are allowed providing that the dose and regimen have been stable for at least 3 months prior to Screening and are expected to remain stable throughout (...) Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2009 Clinical Trials

80. 24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination

Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) 24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination 24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2009 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>